Acute Pyelonephritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major acute pyelonephritis markets reached a value of US$ 183.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 286.4 Million by 2034, exhibiting a growth rate (CAGR) of 4.13% during 2024-2034.
The acute pyelonephritis market has been comprehensively analyzed in IMARC's new report titled "Acute Pyelonephritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute pyelonephritis is a severe and potentially life-threatening bacterial infection that affects the kidneys. It is characterized by the sudden inflammation of the renal parenchyma and renal pelvis, caused mainly by the ascent of bacteria from the urinary tract into the kidneys. Common indications of the illness include pain in the lower back or side, chills, frequent and urgent urination, high fever, and sometimes blood in the urine. Individuals suffering from this ailment may also experience nausea, vomiting, and overall fatigue. Diagnosing the disease involves a combination of clinical assessment, medical history review, and laboratory tests. Healthcare providers may perform a physical examination to assess for specific signs like tenderness over the kidneys. A urinalysis is typically conducted to detect the presence of red blood cells and bacteria in the urine. In more severe cases, imaging studies such as a CT scan or MRI may be used to visualize the kidneys and urinary tract, aiding in the diagnosis and assessment of any anatomical abnormalities.
The increasing cases of urinary tract infections (UTIs) that can result in the rapid onset of inflammation in one or both kidneys are primarily driving the acute pyelonephritis market. In addition to this, the expanding geriatric population, who are more susceptible to chronic conditions like diabetes and kidney stones that can further exacerbate the risk of infections, is creating a positive outlook for the market. Moreover, the widespread adoption of potent antibiotics, such as fluoroquinolones, cephalosporins, aminoglycosides, etc., to counter the bacterial spread and mitigate the inflammatory response in individuals suffering from the illness is also bolstering the market growth. Apart from this, the rising usage of advanced diagnostic modalities, like ultrasound and imaging scans, which aid in accurately pinpointing the site and severity of the infection, is acting as another significant growth-inducing factor. Additionally, numerous pharmaceutical companies are substantially investing in R&D activities to launch effective preventive measures to deter bacterial adherence to the urinary tract is also augmenting the market growth. Furthermore, the escalating demand for cutting-edge technologies, such as nanomedicine and targeted drug delivery, since they can enhance the stability and solubility of poorly soluble drugs, improving their bioavailability in the body, is expected to drive the acute pyelonephritis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acute pyelonephritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute pyelonephritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute pyelonephritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acute pyelonephritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acute pyelonephritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acute pyelonephritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acute pyelonephritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acute pyelonephritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acute pyelonephritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acute pyelonephritis across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute pyelonephritis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute pyelonephritis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acute pyelonephritis across the seven major markets?
What is the size of the acute pyelonephritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acute pyelonephritis?
What will be the growth rate of patients across the seven major markets?
Acute Pyelonephritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acute pyelonephritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute pyelonephritis market?
What are the key regulatory events related to the acute pyelonephritis market?
What is the structure of clinical trial landscape by status related to the acute pyelonephritis market?
What is the structure of clinical trial landscape by phase related to the acute pyelonephritis market?
What is the structure of clinical trial landscape by route of administration related to the acute pyelonephritis market?
The acute pyelonephritis market has been comprehensively analyzed in IMARC's new report titled "Acute Pyelonephritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute pyelonephritis is a severe and potentially life-threatening bacterial infection that affects the kidneys. It is characterized by the sudden inflammation of the renal parenchyma and renal pelvis, caused mainly by the ascent of bacteria from the urinary tract into the kidneys. Common indications of the illness include pain in the lower back or side, chills, frequent and urgent urination, high fever, and sometimes blood in the urine. Individuals suffering from this ailment may also experience nausea, vomiting, and overall fatigue. Diagnosing the disease involves a combination of clinical assessment, medical history review, and laboratory tests. Healthcare providers may perform a physical examination to assess for specific signs like tenderness over the kidneys. A urinalysis is typically conducted to detect the presence of red blood cells and bacteria in the urine. In more severe cases, imaging studies such as a CT scan or MRI may be used to visualize the kidneys and urinary tract, aiding in the diagnosis and assessment of any anatomical abnormalities.
The increasing cases of urinary tract infections (UTIs) that can result in the rapid onset of inflammation in one or both kidneys are primarily driving the acute pyelonephritis market. In addition to this, the expanding geriatric population, who are more susceptible to chronic conditions like diabetes and kidney stones that can further exacerbate the risk of infections, is creating a positive outlook for the market. Moreover, the widespread adoption of potent antibiotics, such as fluoroquinolones, cephalosporins, aminoglycosides, etc., to counter the bacterial spread and mitigate the inflammatory response in individuals suffering from the illness is also bolstering the market growth. Apart from this, the rising usage of advanced diagnostic modalities, like ultrasound and imaging scans, which aid in accurately pinpointing the site and severity of the infection, is acting as another significant growth-inducing factor. Additionally, numerous pharmaceutical companies are substantially investing in R&D activities to launch effective preventive measures to deter bacterial adherence to the urinary tract is also augmenting the market growth. Furthermore, the escalating demand for cutting-edge technologies, such as nanomedicine and targeted drug delivery, since they can enhance the stability and solubility of poorly soluble drugs, improving their bioavailability in the body, is expected to drive the acute pyelonephritis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acute pyelonephritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute pyelonephritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute pyelonephritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acute pyelonephritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acute pyelonephritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acute pyelonephritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acute pyelonephritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acute pyelonephritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acute pyelonephritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acute pyelonephritis across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute pyelonephritis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute pyelonephritis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acute pyelonephritis across the seven major markets?
What is the size of the acute pyelonephritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acute pyelonephritis?
What will be the growth rate of patients across the seven major markets?
Acute Pyelonephritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acute pyelonephritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute pyelonephritis market?
What are the key regulatory events related to the acute pyelonephritis market?
What is the structure of clinical trial landscape by status related to the acute pyelonephritis market?
What is the structure of clinical trial landscape by phase related to the acute pyelonephritis market?
What is the structure of clinical trial landscape by route of administration related to the acute pyelonephritis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACUTE PYELONEPHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACUTE PYELONEPHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACUTE PYELONEPHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ACUTE PYELONEPHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACUTE PYELONEPHRITIS - UNMET NEEDS
10 ACUTE PYELONEPHRITIS - KEY ENDPOINTS OF TREATMENT
11 ACUTE PYELONEPHRITIS - MARKETED PRODUCTS
11.1 List of Acute Pyelonephritis Marketed Drugs Across the Top 7 Markets
11.1.1 Vabomere (Meropenem/vaborbactam) - Melinta Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Levaquin (Levofloxacin) - Daiichi Sankyo
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ACUTE PYELONEPHRITIS - PIPELINE DRUGS
12.1 List of Acute Pyelonephritis Pipeline Drugs Across the Top 7 Markets
12.1.1 TBPM PI HBr - Spero Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 WCK 4282 - Wockhardt
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 WCK5222 - Wockhardt
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Cefepime/Taniborbactam - VenatoRx Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ACUTE PYELONEPHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACUTE PYELONEPHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACUTE PYELONEPHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Pyelonephritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Pyelonephritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Pyelonephritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Pyelonephritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Pyelonephritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Pyelonephritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Pyelonephritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Pyelonephritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Pyelonephritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Pyelonephritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Pyelonephritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Pyelonephritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Pyelonephritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Pyelonephritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Pyelonephritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Pyelonephritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Pyelonephritis - Access and Reimbursement Overview
16 ACUTE PYELONEPHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACUTE PYELONEPHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACUTE PYELONEPHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACUTE PYELONEPHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACUTE PYELONEPHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACUTE PYELONEPHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ACUTE PYELONEPHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACUTE PYELONEPHRITIS - UNMET NEEDS
10 ACUTE PYELONEPHRITIS - KEY ENDPOINTS OF TREATMENT
11 ACUTE PYELONEPHRITIS - MARKETED PRODUCTS
11.1 List of Acute Pyelonephritis Marketed Drugs Across the Top 7 Markets
11.1.1 Vabomere (Meropenem/vaborbactam) - Melinta Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Levaquin (Levofloxacin) - Daiichi Sankyo
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ACUTE PYELONEPHRITIS - PIPELINE DRUGS
12.1 List of Acute Pyelonephritis Pipeline Drugs Across the Top 7 Markets
12.1.1 TBPM PI HBr - Spero Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 WCK 4282 - Wockhardt
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 WCK5222 - Wockhardt
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Cefepime/Taniborbactam - VenatoRx Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ACUTE PYELONEPHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACUTE PYELONEPHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACUTE PYELONEPHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Pyelonephritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Pyelonephritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Pyelonephritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Pyelonephritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Pyelonephritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Pyelonephritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Pyelonephritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Pyelonephritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Pyelonephritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Pyelonephritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Pyelonephritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Pyelonephritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Pyelonephritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Pyelonephritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Pyelonephritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Pyelonephritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Pyelonephritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Pyelonephritis - Access and Reimbursement Overview
16 ACUTE PYELONEPHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACUTE PYELONEPHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACUTE PYELONEPHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
